- Home
- ADAP vs GOSS Comparison
ADAP vs GOSS Comparison
Compare ADAP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- GOSS
- Stock Information
- Founded
- ADAP 2008
- GOSS 2015
- Country
- ADAP United Kingdom
- GOSS United States
- Employees
- ADAP N/A
- GOSS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- GOSS Health Care
- Exchange
- ADAP Nasdaq
- GOSS Nasdaq
- Market Cap
- ADAP 212.3M
- GOSS 212.9M
- IPO Year
- ADAP 2015
- GOSS 2019
- Fundamental
- Price
- ADAP $0.59
- GOSS $0.74
- Analyst Decision
- ADAP Strong Buy
- GOSS Strong Buy
- Analyst Count
- ADAP 4
- GOSS 5
- Target Price
- ADAP $3.16
- GOSS $9.20
- AVG Volume (30 Days)
- ADAP 2.0M
- GOSS 881.6K
- Earning Date
- ADAP 11-13-2024
- GOSS 11-07-2024
- Dividend Yield
- ADAP N/A
- GOSS N/A
- EPS Growth
- ADAP N/A
- GOSS N/A
- EPS
- ADAP N/A
- GOSS N/A
- Revenue
- ADAP $175,041,000.00
- GOSS $105,322,000.00
- Revenue This Year
- ADAP $180.15
- GOSS N/A
- Revenue Next Year
- ADAP N/A
- GOSS N/A
- P/E Ratio
- ADAP N/A
- GOSS N/A
- Revenue Growth
- ADAP 146.27
- GOSS N/A
- 52 Week Low
- ADAP $0.42
- GOSS $0.50
- 52 Week High
- ADAP $2.05
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- ADAP 26.22
- GOSS 22.63
- Support Level
- ADAP $0.75
- GOSS $0.78
- Resistance Level
- ADAP $0.83
- GOSS $0.92
- Average True Range (ATR)
- ADAP 0.07
- GOSS 0.05
- MACD
- ADAP -0.01
- GOSS -0.01
- Stochastic Oscillator
- ADAP 2.36
- GOSS 0.00
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.